

-23-

**ABSTRACT**

5 The invention is encompassed in the technical sector of  
lung cancer treatment with antitumor drugs, and it specifically  
develops a diagnostic device which allows treating each patient  
with the most effective drug according to the polymorphism they  
show for the XPD gene. The assay device of the invention is  
based on the polymorphic variants of the XPD gene at exon 23 (A-  
C, Lys 751 Gln) and at exon 10 (G-A, Asp312Asn) and on the  
development of specific primers which allow detecting said  
10 polymorphisms by PCR or by means of automatic DNA sequencing.

BEST AVAILABLE COPY